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prolonged stable disease provides clinical
benefits for patients in the pivotal trial
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Abstract
Background: Achievement of durable responses in patients with relapsed/refractory peripheral T cell lymphoma
(PTCL) is challenging with current therapies, and there are few data regarding the potential benefits of continuing
treatment in patients with the best response of stable disease (SD). Histone deacetylase inhibitors are a novel class
of drugs with activity in T cell malignancies. Romidepsin was approved by the US Food and Drug Administration
for the treatment of relapsed/refractory PTCL based on a pivotal trial demonstrating an objective response rate of
25 % (33/130), including 15 % with confirmed/unconfirmed complete response and a median duration of response
of 28 months. Our objective was to further study the clinical benefits of romidepsin in patients that had the best
response of SD.
Methods: Patients with PTCL relapsed/refractory to ≥1 prior therapy were treated with the approved dose of
14 mg/m2 romidepsin on days 1, 8, and 15 of six 28-day cycles; patients with SD or response after cycle 6 were
allowed to continue on study until progression. By protocol amendment, patients treated for ≥12 cycles could
receive maintenance dosing twice per cycle; after cycle 24, dosing could be further reduced to once per cycle in
those who had received maintenance dosing for ≥6 months.
Results: Of the 32 patients (25 %) with the best response of SD, 22 had SD for ≥90 days (SD90; cycle 4 response
assessment). The longest SD was >3 years in a patient who received maintenance dosing of 14 mg/m2 on days 1
and 15 beginning in cycle 13. Patients with the best response of SD90 or partial response achieved similar overall
and progression-free survival. Prolonged dosing of romidepsin was well tolerated.
Conclusions: We concluded that patients who achieve SD may consider continuing treatment because the clinical
benefits of romidepsin may extend beyond objective responses.
Trial registration: NCT00426764
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Background
Peripheral T cell lymphoma (PTCL) is a heterogeneous
group of aggressive T cell and natural killer (NK)-cell
disorders typically associated with poor prognosis [1, 2].
Overall, the known subtypes of PTCL comprise ≈5–10 %
of the estimated 71,850 cases of non-Hodgkin lymph-
oma (NHL) diagnosed in the USA in 2015 [2–4]. The
median age has been reported as 62 years, and the most
common PTCL subtypes in North America are PTCL
not otherwise specified (NOS), angioimmunoblastic TCL
(AITL), and anaplastic large cell lymphoma (ALCL); ALCL
is divided into those positive or negative for anaplastic
lymphoma kinase 1 (ALK-1) [4]. Patients with ALK-1-
positive ALCL, who tend to be substantially younger than
patients with other subtypes (median age of 34 years) [5],
generally have improved prognosis compared with other
subtypes [4]. Across all subtypes, increased age is a nega-
tive prognostic factor for survival [4, 6].
Most patients with PTCL receive induction chemother-
apy (e.g., cyclophosphamide, doxorubicin, vincristine, pred-
nisone (CHOP)) as first-line treatment; however, many
patients who respond experience rapid relapse [1, 2, 4, 7,
8]. The use of these anthracycline-based therapies to treat
PTCL is a result of successful treatment of B cell lymph-
omas, [1, 2, 7] although only patients with ALK-1-positive
ALCL typically have a favorable prognosis [4, 8]. Accord-
ingly, National Cooperative Cancer Network (NCCN)
guidelines for patients with ALK-1-positive ALCL recom-
mend first-line treatment with CHOP or CHOEP [8]. Al-
though there are currently no ALK inhibitors approved for
ALK-1-positive ALCL, several are undergoing investigation
[9, 10]. For patients with other PTCL subtypes, promis-
ing results have been observed in early clinical studies
of first-line treatments that combine anthracycline-
based chemotherapy regimens with novel agents (romi-
depsin, brentuximab vedotin, belinostat) [11–13].
According to the NCCN guidelines for PTCL, patients
with relapsed/refractory disease are those with less than
complete response (CR) or loss of CR to first-line therapy
[8]. For patients with relapsed/refractory PTCL, NCCN
guidelines group those with CR or partial response (PR)
and consider stable disease (SD) or progressive disease
(PD) as a lack of response to treatment and a trigger to
switch therapy [8].
Achievement of durable responses in patients with re-
lapsed/refractory PTCL is difficult, and there are few
treatment options [2, 4, 14]. Additionally, a retrospective
analysis of patients with PTCL (N = 205) demonstrated
that objective response rates (ORRs) and progression-
free survival (PFS) decrease with each line of therapy
[15]. Thus, in the setting of relapsed/refractory PTCL,
overall clinical benefit and not just achievement of an
objective response must be carefully considered when
initiating, continuing, stopping, or switching therapies.
There are few data regarding the potential benefits of
continuing therapy for patients with relapsed/refractory
PTCL with best response of SD.
Romidepsin is a histone deacetylase inhibitor approved
by the US Food and Drug Administration for the treat-
ment of cutaneous TCL (CTCL) in patients who have re-
ceived at least one prior systemic therapy and PTCL in
patients who have received at least one prior therapy
[16]. Approval in PTCL was primarily based on results
from the pivotal phase 2, single-arm, open-label study in
patients with relapsed/refractory PTCL (N = 131) [16–18].
This pivotal study demonstrated an ORR of 25 % including
15 % with confirmed/unconfirmed CR (CR/CRu) [16–18]
and a median duration of response (DOR) of 28 months
(median follow-up 22.3 months) [18] with the longest
response ongoing at 56 months [19]. While achieve-
ment of CR/CRu was associated with prolonged survival
vs all other outcomes, patients who achieved PR or SD
for ≥90 days (SD90) had similar long-term outcomes,
and the majority of those with best response of SD had
SD90 [18]. The objective of the analyses reported herein
was to further examine the clinical benefit of SD in patients
with relapsed/refractory PTCL treated with romidepsin in
the pivotal study.
Results
Patient characteristics and disposition
Of the 130 patients with histologically confirmed PTCL,
32 (25 %) had the best response of SD. Baseline patient
characteristics among those with best response of SD
were similar to those of the overall population (Table 1).
The majority of patients (overall or with best response
of SD) had advanced disease (stage III/IV, International
Prognostic Index ≥2, Eastern Cooperative Oncology
Group (ECOG) 1 to 2) and had received ≥2 prior therap-
ies for PTCL. Most discontinuations occurred during cy-
cles 1 to 2 of treatment; 59 patients (45 %) were treated
for ≥3 cycles. The majority of patients with best re-
sponse ≥SD by independent review committee (IRC) as-
sessment who discontinued during cycles 1 and 2 did so
due to PD as assessed by the investigator (two patients
due to adverse events (AEs)). Twenty-four patients
(18 %) received treatment beyond 6 cycles, 18 of whom
(14 %) were treated for ≥12 cycles. Romidepsin dose de-
lays and reductions were most common during cycle 2
(19 and 9 %, respectively) and cycle 3 (15 and 7 %, re-
spectively) of treatment.
Long-term outcomes
Of the 32 patients with the best response of SD, 22
(69 %) had SD90 including 14 of 16 patients with PTCL-
NOS, 3 of 8 patients with AITL, 3 of 5 patients with
ALK-1-negative ALCL, and 2 of 3 patients with rare sub-
types (subcutaneous panniculitis-like TCL and cutaneous
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γδ TCL; Fig. 1). Thus, for the most common subtypes, the
rate of disease control (CR/CRu + PR + SD90) was 49 %
(34/69) for PTCL-NOS, 44 % (12/27) for AITL, and 38 %
(8/21) for ALK-1-negative ALCL. Six patients had SD
for ≥6 months, and the longest SD was > 3 years in dur-
ation (Fig. 1). Of note, 6 patients with best response of
SD (IRC) were found to have a response (5 CR, 1 PR) by
exploratory PET endpoint. All 6 of these patients had
achieved SD90 by IRC assessment (time to progression
(TTP) 112–176 days). For the 6 patients with SD (IRC)
for ≥6 months, 5 also had SD by PET endpoint; 1 did
not have PET assessments (Fig. 1). Three patients with
best response of SD (IRC) were found to have PD by ex-
ploratory PET endpoint, each with a short TTP (IRC) of
41, 49, and 53 days.
As previously reported with an earlier data cutoff
(December 31, 2011) [18], for patients with the best re-
sponse of SD90, PFS and OS were not statistically differ-
ent compared with patients who achieved PR (Fig. 2). The
patient with the longest reported SD (>3 years) was a 61-
year-old woman with stage III PTCL-NOS at diagnosis
and ECOG performance status of 1. Prior systemic therap-
ies included CHOP and oral cyclophosphamide, etoposide,
and cisplatin. The only drug-related event reported was
grade 3 vomiting during cycle 22, which resolved with
prochlorperazine in 2 days and did not result in dose
changes. Beginning at cycle 13, romidepsin was adminis-
tered on an every-other-week schedule (days 1 and 15 of
28-day cycles). This patient discontinued at her request
after 42 months of treatment. Upon review by the IRC,
she was determined to have PD at 38 months of treat-
ment, 4 months before she decided to discontinue. The
patient with the second longest reported SD (≈12 months)
was a 60-year-old man with stage I cutaneous γδ TCL at
diagnosis. Prior therapy included alemtuzumab. Possibly
drug-related AEs included grade 3 pyrexia and cellulitis
during cycle 6 (history of cellulitis prior to trial) and grade
4 neutropenia during cycle 12. He had a dose withheld in
cycle 12 due to infection, pyrexia, and neutropenia and
discontinued romidepsin due to PD after 12 months of
treatment. At the latest follow-up, all patients with best re-
sponse of SD had discontinued romidepsin treatment: 24
(75 %) due to PD, 5 (16 %) due to AEs, 2 (6 %) due to pa-
tient decision, and 1 (3 %) due to insufficient response.
Toxicity
Similar to what was reported for the overall population
[17], the most commonly reported any grade AEs in
patients with best response of SD were nausea, asthenia/
fatigue, infections (all types pooled), and dysgeusia
(Table 2). Nearly all patients with best response of SD ex-
perienced ≥1 AE (31/32 (97 %)); this included 30 (94 %)
with drug-related AEs, 23 (72 %) with grade ≥3 AEs, and
19 (59 %) with grade ≥3 drug-related AEs. Neutropenia,
thrombocytopenia, infections (all types pooled), and
anemia were the only grade ≥3 AEs reported in >1 patient
with best response of SD. Incidence of any grade drug-
related AEs was highest during cycle 1. Patients with best
response of SD to romidepsin experienced AEs through-
out their treatment; though, notably, all patients with AEs
reported after cycle 6 had ≥1 drug-related AE, and non-
drug-related grade ≥3 AEs occurred rarely after cycle 2
(Fig. 3).
Of the 32 patients with best response of SD, 20 patients
(63 %) and 6 patients (19 %) had ≥1 dose interruption
Table 1 Key baseline patient demographics and characteristics
Characteristic Overall
(N = 130)a
Patients with
best response
of SD (n = 32)
Age, median (range), y 61 (20–83) 61.5 (24–79)
ECOG performance statusb
0 46 (35) 10 (31)
1 66 (51) 17 (53)
2 17 (13) 5 (16)
International Prognostic Index, n (%)
<2 31 (24) 7 (22)
≥2 99 (76) 25 (78)
PTCL subtype based on central review, n (%)
PTCL-NOS 69 (53) 16 (50)
AITL 27 (21) 8 (25)
ALK-1-negative ALCL 21 (16) 5 (16)
Other 13 (10)c 3 (9)d
Stage III/IV at diagnosis, n (%) 91 (70) 20 (63)
Number of prior therapies, n (%)
1 38 (29) 13 (41)
2 44 (34) 11 (34)
3 19 (15) 3 (9)
4 15 (12) 4 (13)
>4 14 (11) 1 (3)
Type of prior therapy, n (%)
Chemotherapy 129 (99) 31 (97)
Monoclonal antibody therapy 20 (15) 3 (9)
Other immunotherapy 14 (11) 1 (3)
Radiation 31 (24) 8 (25)
ASCT 21 (16) 3 (9)
Refractory to most recent therapy, n (%) 49 (38) 8 (25)
ASCT autologous stem cell transplant
a PTCL histologically confirmed by central pathology review
b One patient in the overall population had missing ECOG performance status
at baseline
cIncludes enteropathy-associated TCL (6), subcutaneous panniculitis-type TCL
(3), ALK-1-positive ALCL (1), cutaneous γδ TCL (1), extranodal NK/TCL nasal
type (1), and transformed mycosis fungoides (1)
dIncludes enteropathy-type TCL (1), subcutaneous panniculitis-like TCL (1), and
cutaneous γδ TCL (1)
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and/or dose reduction due to AEs, respectively. Five of 32
patients with best response of SD discontinued romidep-
sin due to the following AEs: ventricular extrasystoles and
decreased T wave amplitude (probably drug related; cycle
1); neutropenia (drug related; cycle 3); acute angle-closure
glaucoma (possibly drug related; cycle 4); pulmonary em-
bolism, elevated C-reactive protein, and melanoma (only
melanoma was possibly drug related; cycle 6); and pneu-
monia (not drug related; cycle 9).
Discussion
Three HDAC inhibitors have been approved by the US
Food and Drug Administration for the treatment of
TCL: romidepsin for patients with CTCL who have re-
ceived ≥1 prior systemic therapy and for patients with
PTCL who have received ≥1 prior therapy, vorinostat for
cutaneous manifestations in patients with CTCL who
have progressive, persistent, or recurrent disease on or
following two systemic therapies, and belinostat for pa-
tients with relapsed or refractory PTCL [16, 20, 21]. In a
pivotal phase 2 trial of patients with relapsed/refractory
PTCL, single-agent belinostat was able to induce an
ORR of 26 % (31/120 patients), including 11 % with
complete response, and a DOR of 14 months. The me-
dian PFS and OS were 1.6 and 7.9 months, respectively,
and common (>5 %) grade 3/4 adverse events included
anemia (11 %), thrombocytopenia (7 %), dyspnea (6 %),
and neutropenia (6 %) [22].
Single-agent romidepsin has been shown to lead to
durable responses (median DOR >2 years [18]) in
patients with relapsed/refractory PTCL regardless of
baseline demographic and disease characteristics, includ-
ing age, PTCL subtype, number or types of prior therap-
ies, and response to prior therapy [17, 18]. The majority
of responses (33/130; 25 % ORR) in the pivotal study
were noted at the first response assessment (during cycle
2), and all were noted within the predetermined trial
length of 6 cycles [18]. Although the NCCN guidelines
for relapsed/refractory PTCL consider SD as a lack of re-
sponse to treatment and a trigger to switch therapy [8],
the protocol for the pivotal study of romidepsin allowed
for continued treatment in patients with SD at the
discretion of the patient and investigator. Thirty-two of
the 130 patients (25 %) who did not achieve an objective
response experienced disease stabilization, with most
(22/32 (69 %)) achieving SD90 (response assessed as SD
during cycles 2 and 4). Prolonged disease stabilization
does not appear to be a result of inadequate response
assessment, as the patients with SD ≥6 months by IRC
assessment also had best response of SD by exploratory
PET endpoint.
Although only six patients (19 %) achieved disease
stabilization for ≥6 months, outcomes in terms of PFS
and OS were similar for patients achieving PR or SD90.
Rates of disease control (CR/CRu + PR + SD90) were 49,
44, and 38 for patients with PTCL-NOS, AITL, and
ALK-1-negative ALCL, respectively. As a result of ex-
tended treatment in many patients, the pivotal study
protocol was amended to allow for maintenance dosing
after ≥12 treatment cycles.
Fig. 1 TTP and duration of treatment in patients with best response of SD to romidepsin. PTCL subtypes and response by exploratory PET
endpoint are shown on Y axis. Vertical line indicates 90 days of treatment; asterisk indicates patients that discontinued due to adverse event; and
dagger sign indicates patients that discontinued due to patient decision. E-type TCL enteropathy-type T cell lymphoma, P-like TCL subcutaneous
panniculitis-like T cell lymphoma
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It was previously reported that prolonged treatment
with romidepsin did not affect the safety profile, and the
highest incidence of grade ≥3 AEs occurred during cy-
cles 1 to 2 of treatment [18]. Additionally, most discon-
tinuations and dose modification occurred early in
treatment (cycles 1 to 2 and 2 to 3, respectively). The
most common AEs reported included gastrointestinal
disturbances, hematologic abnormalities, asthenic condi-
tions, and infections (all types pooled) [16–18]. There
were no clinically significant changes in QT intervals
across treatment cycles, and ECG abnormalities were
uncommon. A recently published ECG study of romi-
depsin asserted the cardiac safety of romidepsin while
stressing the need for appropriate potassium and/or
magnesium supplementation throughout treatment [23].
Results from a thorough post-marketing cardiac study in
patients with advanced malignancies also assert that
despite the use of QT-prolonging antiemetics, romidep-
sin treatment did not significantly prolong QTc, even at
supratherapeutic doses; reported increases in calculated
QTc were exaggerated due to transient heart rate in-
creases [24]. The AE profile for patients with best re-
sponse of SD was similar to that of the overall
population. Although the majority of patients with best
response of SD experienced grade ≥3 AEs, <20 % re-
quired dose reductions and/or discontinued due to AEs.
Patients with SD who received prolonged romidepsin
treatment did experience AEs late in treatment, but only
one patient discontinued due to AEs after cycle 6.
Conclusions
The data shown herein demonstrated the feasibility and
clinical benefit of prolonged administration of romidep-
sin in patients who achieved at least SD on therapy.
Fig. 2 Survival based on clinical IRC assessment by best response to romidepsin (n = 130). Progression-free survival (a) and overall survival (b).
Patients with insufficient efficacy data to determine response due to early termination (NE; n = 29) were included as nonresponders. NE
not evaluable
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Durability of responses in patients with relapsed/refrac-
tory PTCL remains a challenge with current treatment
options [2, 4, 14], and both response rates and survival
appear to decrease with increasing lines of prior therapy
[15]. Durability of both objective responses and SD as
well as long-term tolerability reported with romidep-
sin also warrants further investigation in studies of
maintenance therapy after first-line chemotherapy or
stem cell transplant in patients with PTCL.
Methods
Study design
The study design and eligibility criteria for this prospect-
ive, single-arm, open-label, international phase 2 study
Table 2 Most common AEs by treatment cycle in patients with best response of SD to romidepsin
Drug related/non-drug
related, n
Treatment cycle
Any (n = 32) 1 (n = 32) 2 (n = 28) 3 (n = 25) 4 (n = 21) 5 (n = 14) 6 (n = 11) >6 (n = 5)
Any grade AEs reported in > 20 % of patients with best response of SD
Nausea 22/2 18/2 6/0 5/0 5/1 5/0 0/0 1/0
Asthenia/fatigue 19/1 13/0 6/0 4/0 4/0 3/1 2/1 1/0
Infections SOC 6/11 4/6 1/3 1/2 0/5 1/1 1/2 1/2
Dysgeusia 14/0 8/0 7/0 1/0 2/0 0/0 0/0 0/0
Vomiting 12/1 5/0 4/1 4/0 3/1 4/0 0/0 1/0
Diarrhea 7/5 5/1 4/2 1/0 1/0 0/1 0/1 1/0
Constipation 5/6 3/3 0/0 2/0 0/0 1/1 0/0 0/1
Anorexia 11/0 6/0 3/0 3/0 1/0 2/0 0/0 1/0
Thrombocytopenia 10/0 6/0 2/0 3/0 2/0 2/0 2/0 0/0
Pyrexia 7/1 1/1 1/0 0/1 2/1 1/1 1/1 1/1
Neutropenia 7/0 4/0 4/0 3/0 2/0 1/0 1/0 2/0
Anemia 6/1 1/1 2/0 1/0 1/0 0/0 1/0 2/0
Grade≥ 3 AEs reported in > 1 patients with best response of SD
Neutropenia 7/0 4/0 3/0 2/0 1/0 1/0 0/0 2/0
Thrombocytopenia 6/0 3/0 1/0 1/0 1/0 1/0 1/0 0/0
Infections SOC 2/3 1/2 0/0 0/0 0/0 0/0 1/0 0/2
Anemia 3/0 0/0 1/0 0/0 0/0 0/0 1/0 1/0
Patients who experienced drug-related events may have also experienced non-drug-related events
SOC system organ class
Fig. 3 Patients with AEs by cycle in patients with best response of SD to romidepsin. Numbered bars represent the number of patients with SD
treated in each cycle. Those who experienced drug-related AEs may have also experienced non-drug-related AEs
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were previously described (Clinicaltrials.gov identifier:
NCT00426764) [17]. The following PTCL subtypes [25]
were eligible: PTCL-NOS, AITL, extranodal NK/TCL
nasal type, enteropathy-type TCL, subcutaneous
panniculitis-like TCL, cutaneous γδ TCL, hepatosple-
nic TCL, ALK-1-negative ALCL, ALK-1-positive ALCL
(restricted to patients with disease relapse post autolo-
gous stem cell transplant), and transformed mycosis
fungoides (nontransformed mycosis fungoides and
Sézary syndrome excluded). Diagnosis of PTCL was
histologically confirmed by local pathologists, and
PTCL subtyping was reviewed by a central laboratory
(Celligent Diagnostics, Charlotte, NC). Briefly, eligible
patients had PTCL relapsed or refractory to ≥1 systemic
therapy with measurable disease according to Inter-
national Working Group (IWG) criteria [26] and/or
measurable cutaneous disease, an Eastern Cooperative
Oncology Group (ECOG) performance status of 0 to 2
at enrollment, adequate bone marrow and organ function
(including no known significant cardiac abnormalities),
and serum potassium and magnesium concentrations ≥3.8
and ≥0.85 mmol/L, respectively. The need for electrolyte
supplementation is common for patients with TCL
[23, 27], and hypokalemia and/or hypomagnesemia are
known risk factors for cardiac arrhythmia and sudden
cardiac death [28–31] and may be associated with
electrocardiogram (ECG) abnormalities [32, 33]. Low
levels of potassium and/or magnesium could be cor-
rected by supplementation to meet the inclusion criteria
throughout the trial.
Patients received romidepsin 14 mg/m2 as a 4-h intra-
venous infusion on days 1, 8, and 15 of each 28-day
cycle (Food and Drug Administration-approved dosing
in both PTCL and CTCL [16]) for up to 6 cycles. Pa-
tients with at least SD could continue treatment beyond
6 cycles at the discretion of the patient and investigator.
By protocol amendment, patients treated for ≥12 cycles
could receive maintenance dosing of two rather than
three doses per 28-day cycle. After cycle 24, dosing
could be further reduced to once per cycle in those who
has received maintenance dosing for ≥6 months.
The protocol, informed consent form, and other rele-
vant study documentation were approved by the institu-
tional review boards of all participating institutions. All
patients gave written informed consent prior to study
entry.
Efficacy and safety assessments
The efficacy and safety assessments conducted were pre-
viously described in detail [17]. Response was assessed
every 2 cycles (during days 22–28, completed prior to
treatment in next cycle) by site investigators and an in-
dependent review committee (IRC) according to the
1999 IWG criteria guidelines for response assessments
for NHL [26]. IRC assessments were primary and inves-
tigator assessments were considered supportive. The pri-
mary endpoint was rate of CR/CRu, and key secondary
efficacy endpoints included ORR, DOR, and time to dis-
ease progression. Time to response as well as survival
(PFS and overall survival [OS]) by best response to romi-
depsin at any time on trial was also assessed. The utility
of positron emission tomography (PET) in this patient
population was examined as a prospective exploratory
endpoint, with responses assessed by IWG + PET criteria
[34]. Full results for this endpoint were presented in a
separate publication [35].
In the analyses herein, SD90 was defined as patients with
the best response of SD with time to progression ≥90 days,
which corresponded with a response assessment of SD
during cycles 2 and 4. Adverse events (AEs) were docu-
mented according to the Medical Dictionary for Regulatory
Activities (version 12.0) and the National Cancer Institute
Common Terminology Criteria for Adverse Events
(version 3.0). Drug-related AEs were those indicated by
the investigator as having at least a possible relationship
to romidepsin or missing a relationship assessment.
Statistical methods
Patients with the best response of SD were the primary
focus of this analysis. All descriptive statistical analyses
were performed using SAS statistical software, version
9.2 (SAS Institute). Time-to-event data were summa-
rized by Kaplan-Meier methods. This study is ongoing,
but September 30, 2012, was the cutoff date for this ana-
lysis. Patients who withdrew from the trial without PD
were to be assessed every 2 months until PD, at with-
drawal from follow-up, or at start of alternate therapy.
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